Prophylaxe oder Prävention?

Der Freie Zahnarzt - Diese beiden Begriffe bedeuten im Grunde dasselbe, nämlich Vorbeugung. „Prophylaxe“ ist aus dem Griechischen und „Prävention“ aus dem...     

Klare Verhältnisse auch bei submukös selbstständigen Vestibulumplastiken

Der Freie Zahnarzt - Eine Vestibulumplastik ist ein Schleimhaut formender intraoraler Eingriff zur operativen Schaffung und/oder Verbesserung des Mundvorhofs, auch zur Gingivaverbreiterung. Wie...     

Zahntechnische Materialien: Welche Auslage wird ersetzt?

Der Freie Zahnarzt - Die Kassenzahnärztliche Bundesvereinigung (KZBV) und die Bundeszahnärztekammer (BZÄK) haben im Oktober 2015 die 1. Auflage einer gemeinsamen Broschüre zum...     

Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?

Purpose Patients with somatostatin receptor subtype 2-positive metastasised neuroendocrine tumours can be treated with [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate. Some use octreotide as the peptide for peptide receptor radionuclide therapy (PRRT). We compared in seven patients [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotide (¹⁷⁷Lu-DOTATOC) and [¹⁷⁷Lu-DOTA⁰,Tyr³]octreotate (¹⁷⁷Lu-DOTATATE), to see which peptide should be preferred for PRRT with ¹⁷⁷Lu.Methods In the same patients, 3,700 MBq ¹⁷⁷Lu-DOTATOC and 3,700 MBq ¹⁷⁷Lu-DOTATATE was administered in separate therapy sessions. Amino acids were co-administered. Whole-body scanning was performed on days 1, 4 and 7 post therapy. Blood and urine samples were collected. We calculated residence times for tumours, spleen and kidneys.Results All patients had longer residence times in spleen, kidneys and tumours after use of ¹⁷⁷Lu-DOTATATE (p=0.016 in each case). Comparing ¹⁷⁷Lu-DOTATATE with ¹⁷⁷Lu-DOTATOC, the mean residence time ratio was 2.1 for tumour, 1.5 for spleen and 1.4 for kidneys. Dose-limiting factors for PRRT are bone marrow and/or kidney dose. Although the residence time for kidneys was longer when using ¹⁷⁷Lu-DOTATATE, the mean administered dose to tumours would still be advantageous by a factor of 1.5, assuming a fixed maximum kidney dose is reached. Plasma radioactivity after ¹⁷⁷Lu-DOTATATE was comparable to that after ¹⁷⁷Lu-DOTATOC. Urinary excretion of radioactivity was comparable during the first 6 h; thereafter there was a significant advantage for ¹⁷⁷Lu-DOTATOC.Conclusion ¹⁷⁷Lu-DOTATATE had a longer tumour residence time than ¹⁷⁷Lu-DOTATOC. Despite a longer residence time in kidneys after ¹⁷⁷Lu-DOTATATE, tumour dose will always be higher. Therefore, we conclude that the better peptide for PRRT is octreotate.     

The triple flash electroretinogram and its significance in macular diseases

Purpose: The purpose of this study was to evaluate recovery data for the b-wave of the electroretinogram (ERG) elicited using multiple flash stimulation with increasing stimulus intervals in normal controls and in patients with macular diseases. The results will describe effects of age and macular disease and define indexes characterizing the recovery process. Methods: Scotopic Ganzfeld flash ERGS were elicited using interstimulus intervals of 140, 280, and 560 ms. Relative b-waves were calculated as the ratio b_{140 ms}/ b_{560 ms} and b_{280 ms}/b_{560 ms}, respectively. Responses obtained in 134 eyes of 134 normal controls served as reference data. Fifty-four patients with different macular diseases were also examined and their data compared to the reference data. Results: Relative b-wave amplitudes correlated with interstimulus interval and with flash luminance, but not with age. All patients had a normal ERG when recorded following the standard of clinical electroretinography. A sigmoidal model was suggested, providing three indexes characterizing the b-wave recovery process. Relative b-waves and recovery indexes varied in age-related macular degeneration, central serous retinopathy, vitelliform macular degeneration, Stargardt's disease, and pattern dystrophy. Conclusion: The triple flash ERG reflects energy-yielding and -utilizing mechanisms. It proved to be more sensitive in detecting functional lesions in macular diseases than the standardized explorating procedure. The b-wave recovery model allows differentiation between two independent mechanisms contributing to the b-wave recovery process. One or more of the three characterizing indexes are affected in different macular diseases.     

Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders (PVR and PDR)

Basic fibroblast growth factor (bFGF) has been shown to be involved in epiretinal membrane formation in proliferative vitreoretinal disorders. However, up to now, little knowledge exists, as to the actual cellular source of this potent mitogen.We examined 20 epiretinal membranes from patients with proliferative diabetic retinopathy (PDR) (n = 12) and proliferative vitreoretinopathy (PVR) (n = 8) for the presence of bFGF peptide, fibroblast growth factor receptor-1 (FGFR-1) and bFGF messenger ribonucleic acid (mRNA).Using a specific antibody, we detected bFGF peptide in most (8/10) examined PDR membranes and in all (8/8) PVR membranes. Moreover, we found positive staining for the corresponding receptor.Local production of bFGF in epiretinal membranes was confirmed by nonisotopic in situ hybridisation for bFGF mRNA in some (4/7) examined PDR membranes and some (3/4) examined PVR membranes. All membranes which contained bFGF mRNA were also positive for bFGF peptide.In conclusion, bFGF is produced and stored in epiretinal membranes. Together with the corresponding receptor, bFGF may play a role in the auto- and paracrine control of the proliferative processes at the vitroretinal interface.Abbreviations aFGF acidic fibroblast growth factor - bFGF basic fibroblast growth factor - FGFR-1 fibroblast growth factor receptor-1 - mRNA messenger ribonucleic acid